Bliss GVS Pharma Limited

BLISSGVS

INE416D01022

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 02:22:37 2024-04-30 am EDT			5-day change	1st Jan Change
122.8 ^INR	-1.29%		+7.32%	-1.81%

Jan. 23	Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Bliss GVS Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

Bliss GVS Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

April 30, 2022 at 11:17 am EDT

Bliss GVS Pharma Limited at its board meeting held on April 30, 2022 recommended final dividend of 50% that is INR 0.50 per equity share on face value of INR 1 each for the financial year ended March 31, 2021, to the upcoming annual general meeting to be held on June 28, 2022.

Latest news about Bliss GVS Pharma Limited

Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 23	CI
Bliss GVS Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 01	CI
Assistant Commission of State Tax Maharashtra, Mumbai Initiates Search At Certain Premises of Bliss GVS Pharma Limited	23-09-07	CI
Bliss Gvs Pharma Limited Announces Change in the Designation of Mr. Vishal Vijay Rao	23-08-01	CI
Bliss GVS Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-01	CI
Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2023	23-07-19	CI
Bliss GVS Pharma Gets Establishment Inspection Report from US FDA for Palghar, India Unit	23-06-15	MT
Bliss Gvs Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023	23-05-11	CI
Bliss GVS Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	23-05-11	CI
Bliss GVS Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-11	CI
Infomerics Keeps BBB Rating on Bliss GVS Pharma's Bank Financing; Outlook Stable	23-04-10	MT
Bliss GVS Pharma Gets Three Observations from US FDA's Plant Inspection in Maharashtra, India	23-03-20	MT
Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-01-24	CI
Bliss GVS Pharma Names New CFO	22-12-30	MT
Bliss GVS Pharma Limited Appoints Mr. Deepak Sawant as Chief Financial Officer	22-12-30	CI
Bliss GVS Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-07	CI
Bliss GVS Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-03	CI
Bliss GVS Pharma Limited Declares Final Dividend for the Financial Year Ended March 31, 2022	22-06-28	CI
Bliss GVS Pharma CFO Resigns	22-06-02	MT
Bliss GVS Pharma Limited Announces Resignation of Mr. Vipul B. Thakkar as Chief Financial Officer	22-06-02	CI
Bliss GVS Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	22-04-30	CI
Bliss GVS Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2022	22-04-30	CI
Bliss GVS Pharma Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022	22-04-30	CI
Bliss GVS Pharma Forms New Subsidiary in Congo	22-01-30	MT
Bliss GVS Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	22-01-29	CI

Chart Bliss GVS Pharma Limited

Duration

Period

More charts

Company Profile

Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Companyâs product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Companyâs other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.

Sector

Pharmaceuticals

Calendar

2024-05-16 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
BLISS GVS PHARMA LIMITED	-1.81%	156M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+20.35%	43.75B
OTSUKA HOLDINGS CO., LTD.	+27.47%	22.06B
SANDOZ GROUP AG	+13.30%	14.46B
CIPLA LIMITED	+13.39%	13.62B
ZYDUS LIFESCIENCES LIMITED	+39.30%	11.61B
ONO PHARMACEUTICAL CO., LTD.	-9.54%	6.9B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+9.64%	5.32B